文献速递肿瘤 PET/CT核素与放射性配体治疗

PDL1 PET与SPECT显像的现状与未来展望

Current and Future Perspectives of PDL1 PET and SPECT Imaging.
PubMed 文献 · Semin Nucl Med · 2024-11-06

PD1-PDL1在肿瘤微环境中帮助癌细胞逃避免疫监视,相关抑制剂已用于临床。免疫组化检测存在挑战,促使人们开发用PET或SPECT放射性核素标记PD1和PDL1抑制剂的非侵入性显像方法。本综述阐述当前靶向PD1-PDL1轴的PET和SPECT放射性药物,并探讨新靶点的未来潜在作用。

要点

  • PD1-PDL1帮助癌细胞逃避免疫,相关抑制剂已用于临床并有更多处于临床前阶段。
  • 免疫组化检测存在重大挑战,促使开发靶向PD1和PDL1的PET或SPECT放射性药物。
  • 这些放射性药物主要面向免疫治疗领域,在优化放射性药物治疗与PD1-PDL1靶向抗癌药联合方面有较大潜力。

核心结论

  • 本综述阐述当前靶向PD1-PDL1轴的PET和SPECT放射性药物,并探讨正在临床前研究中开发测试的新靶点的未来潜在作用。

研究设计与样本

  • 本文为综述,阐述当前可用的靶向PD1-PDL1轴的PET和SPECT放射性药物,并探讨新靶点的未来潜在作用。

主要发现

  • PD1和PDL1通过帮助癌细胞逃避免疫在肿瘤微环境中起关键作用。
  • 众多靶向PD1-PDL1相互作用的抑制剂抗癌药已用于临床实践,更多处于临床前阶段。
  • 这些药物在获得良好缓解和长期临床获益方面显示有希望的结果,常规进行检测以识别可能获益的患者。
  • 免疫组化检测存在重大挑战,为非侵入性PET或SPECT显像提供了空间。
  • 这些放射性药物主要开发用于免疫治疗领域,在扩展和优化放射性药物治疗与PD1-PDL1靶向抗癌药的联合方面有较大潜力。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Programmed Death 1 (PD1) and Programmed Death Ligand (PDL1) play a crucial role in tumor microenvironment by helping cancer cells evade innate immunity. Numerous inhibitor anticancer drugs targeting this interplay have been used in clinical practice and many more are in preclinical stage. These drugs have shown promising results in achieving good response and long-term clinical benefit, is routinely performed to identify patients who may benefit. However, there are major challenges associated with these immunohistochemistry tests which have opened the space for noninvasive imaging modalities using PD1 and PDL1 inhibitors labeled with either PET or SPECT radionuclides. These radiopharmaceuticals, although primarily developed for the field of immunotherapy, have great potential in expanding and optimizing the combination of radiopharmaceutical therapies with PD1-PDL1 targeting anticancer drugs. This review elaborates currently available PET and SPECT radiopharmaceuticals targeting PD1-PDL1 axis. It also explores the potential future role of newer targets which are being developed and tested in various preclinical studies.

来源:Semin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Dev ID, Puranik AD, Singh B, et al. Current and Future Perspectives of PDL1 PET and SPECT Imaging. Semin Nucl Med. 2024. PMID: 39510854. doi:10.1053/j.semnuclmed.2024.09.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。